Skip to main content
Teva Pharmaceutical Industries Ltd. logo

Teva Pharmaceutical Industries Ltd. — Investor Relations & Filings

Ticker · TEVA ISIN · US8816242098 LEI · 549300BAFGM4RC74ZJ94 TA Manufacturing
Open in API
Filings indexed 6,049 across all filing types
Latest filing 2026-03-09 Director's Dealing
Country IL Israel
Listing TA TEVA

About Teva Pharmaceutical Industries Ltd.

https://www.tevapharm.com/

Teva Pharmaceutical Industries Ltd. is a global biopharmaceutical company that develops, produces, and markets a broad portfolio of medicines. The company's business is centered on two main segments: generic medicines and innovative specialty treatments. As one of the world's largest manufacturers of generic drugs, Teva provides a wide range of affordable products across numerous therapeutic areas. Its specialty and biopharmaceutical research focuses on developing novel treatments, with a significant emphasis on central nervous system (CNS) disorders, including therapies for schizophrenia, tardive dyskinesia, and bipolar disorder. The company's portfolio also includes complex generics, biosimilars, and active pharmaceutical ingredients (APIs), while leveraging advanced technologies to enhance drug development and manufacturing.

Recent filings

Filing Released Lang Actions
Immediate Report
Director's Dealing Classification · 1% confidence The document is a short regulatory filing (under 2,000 characters) from Teva Pharmaceutical Industries. It explicitly states 'Attached hereto is a report on דיווח מיידי – שינוי בהחזקות נושא משרה' (Immediate Report - Change in Officer Holdings) and provides a PDF filename. According to the 'Menu vs Meal' rule, since this is a short announcement of an attached report regarding director/officer dealings, it is classified as a Report Publication Announcement (RPA).
2026-03-09 English
Immediate Report
Director's Dealing Classification · 1% confidence The document is a SEC Form 4, which is the standard regulatory filing used to report transactions in company securities by directors, officers, and beneficial owners. This falls under the 'Director's Dealing' category as it details the acquisition of shares and the vesting of restricted share units by a company officer (Chief Accounting Officer).
2026-03-09 English
Immediate Report
Report Publication Announcement Classification · 1% confidence The document is a short regulatory filing from Teva Pharmaceutical Industries titled 'Immediate Report – Change in Officer Holdings' (דיווח מיידי – שינוי בהחזקות נושא משרה). It explicitly states that a report regarding the change in officer holdings is attached as a PDF file. According to the 'Menu vs Meal' rule, since this is a short announcement providing a link/attachment to the actual report rather than the report itself, it is classified as a Report Publication Announcement (RPA).
2026-03-09 English
Immediate Report
Director's Dealing Classification · 1% confidence The document is a U.S. Securities and Exchange Commission (SEC) Form 4, which is the standard regulatory filing used to report changes in beneficial ownership of securities by company insiders (directors and officers). The text explicitly identifies the document as 'FORM 4' and 'STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES'. This falls directly under the 'Director's Dealing' category, as it details share transactions (acquisitions and sales) by the CEO, Richard D. Francis.
2026-03-07 English
Immediate Report
Director's Dealing Classification · 1% confidence The document is a short regulatory filing (1846 characters) from Teva Pharmaceutical Industries titled 'Immediate Report – Change in Officer Holdings'. It explicitly states that a report regarding the change in officer holdings is attached as a PDF ('Form_4_-_Richard_Francis_-_6_3_2026_isa.pdf'). According to the 'Menu vs Meal' rule, since this is a short announcement of an attached report rather than the detailed insider trading report itself, it is classified as a Report Publication Announcement (RPA).
2026-03-07 English
Immediate Report
Director's Dealing Classification · 1% confidence The document is a U.S. Securities and Exchange Commission Form 4, which is the standard filing used to report changes in beneficial ownership of securities by company insiders (directors and officers). This falls under the category of 'Director's Dealing' as it details personal share transactions, including the acquisition and sale of shares by an executive (Richard Daniell, EVP, Europe Commercial) of Teva Pharmaceutical Industries.
2026-03-07 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.